A week-old policy statement from the US Department of Health and Human Services that stripped the Food and Drug Administration of its oversight of laboratory developed tests indeed applies to all LDTs and not just those for COVID-19, legal experts tell Medtech Insight.
While the HHS announcement refers to the coronavirus pandemic three times, the core policy declaration – the FDA “will not require premarket review of laboratory developed tests absent notice-and-comment rulemaking,...